Radiolabeled Monoclonal Antibodies
Year: 2003
Type: book-chapter
Abstract: By targeting therapy to specific cell types and disease sites, monoclonal antibodies (MAbs) offer the possibility of improved efficacy and decreased toxicity compared with conventional chemotherapy. Nonetheless, the optimistic view of the early 1980s that MAbs were “magic bullets” has now been replaced by a more realistic understanding of their therapeutic potential. Since the 1980s various strategies employing MAbs for the treatment of cancer have evolved. Native MAbs can be used to focus an inflammatory response against a tumor cell. The binding of a MAb to a target cell can result in complement activation, thereby initiating several biologically important effects, including the induction of chemotaxis for phagocytic cells and the production of the membrane attack complex that disrupts cell membrane integrity. Anther important mechanism for tumor cell killing is antibody-dependent cell-mediated cytotoxicity (ADCC), in which an effector cell expressing an Fc receptor binds to a cell-bound MAb and is triggered to kill the target cell. Examples of antibodies with intrinsic immunologically mediated antitumor activity include the chimeric anti-CD20 antibody rituximab (1) and the humanized anti-CD52 antibody CAMPATH-1H for chronic lymphocytic leukemia (CLL) (2).
Source: Humana Press eBooks
Authors: John M. Burke, Joseph G. Jurcic
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W64848736